Yusheng Wang (Guangyu Wang)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Chronic Kidney Disease

Metastatic Colorectal Cancer

Ejection Fraction

Top Venues

Current cancer drug targets

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Zhuanxia Dong, Zefeng Yang, Jing Ren, Feng Li, Yusheng Wang, Yuanyuan Yu
Envafolimab Inhibits the Growth of Gastric Cancer Cells with Low PD-L1 Expression through the DDX20/NF-κB/TNF-α Signaling Pathway. Current cancer drug targets (2024)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Yuan Wang, Fengyi Liu, Xiaoxue Du, Jiaqi Shi, Rui Yu, Shuang Li, Ruisi Na, Ying Zhao, Meng Zhou, Ying Guo, Liang Cheng, Yusheng Wang, Tongsen Zheng
Combination anti-PD-1 and electroacupuncture induces a potent anti-tumor immune response in microsatellite-stable colorectal cancer. Cancer immunology research (2023)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)
Qianhao Meng, Jian Zhao, Yuanyuan Yu, Ke Wang, Jing Ren, Chang Xu, Yusheng Wang, Guangyu Wang
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC cancer 23 (1) (2023)